[Chemotherapy for human immunodeficiency virus infection. Current status and perspectives].
The role of drugs inhibiting viral replication in patients infected with HIV has been confirmed. Until now only dideoxynucleosides, which are reverse transcriptase inhibitors, have demonstrated antiviral activity in humans. A number of compounds acting on other steps of the viral cycle are currently being evaluated and clinical trials are being performed. Some investigators are attempting to inhibit the binding of viral particles to target cells and their penetration into these by acting on the interaction between HIV ant the CD4 molecule. Another approach consists in the characterization of enzymatic activities which are specific of HIV, other than reverse transcriptase, such as ribonuclease H, integrase or protease, in order to prepare specific inhibitors. Attempts are made to inhibit retroviral gene expression and production of viral particles in infected cells. The development of new nucleoside analogues and drugs with mechanisms of action and toxicities different from those of zidovudine should allow in the near future combination chemotherapy of HIV infection.
Service de Maladies Infectieuses, Hôpital de la Croix Rousse, Lyon.
C
C
Dumontet
F
F
Biron
A
A
Boibieux
B
B
Allaouchiche
D
D
Peyramond
D015224:Dideoxynucleosides / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D014158:Transcription, Genetic / Q000187:drug effects; D016662:Virus Integration / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D015224:Dideoxynucleosides
Chimiothérapie de l'infection par le virus de l'immunodéficience humaine. Etat actuel et perspectives.